(S)-2-tert-butoxycarbonylamino-4-(tert-butyl-dimethyl-silanyloxy)-butyric acid cyclopentyl ester | 914382-63-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-tert-butoxycarbonylamino-4-(tert-butyl-dimethyl-silanyloxy)-butyric acid cyclopentyl ester
• 英文别名: cyclopentyl N-(tert-butoxycarbonyl)-O-[tert-butyl(dimethyl)silyl]-L-homoserinate；cyclopentyl (2S)-4-[tert-butyl(dimethyl)silyl]oxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate
• CAS: 914382-63-1
• 化学式: C₂₀H₃₉NO₅Si
• 分子量: 401.619
• InChiKey: GZJOSOBXIGIFQC-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.78
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-2-tert-butoxycarbonylamino-4-(tert-butyl-dimethyl-silanyloxy)-butyric acid cyclopentyl ester 在 偶氮二甲酸二异丙酯 、 水 、 溶剂黄146 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 32.0h， 生成 (S)-2-tert-butoxycarbonylamino-4-(3-nitro-phenoxy)-butyric acid cyclopentyl ester
  参考文献：
  名称：

  WO2006/117548

  摘要：

  公开号：
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 4-二甲氨基吡啶 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-2-tert-butoxycarbonylamino-4-(tert-butyl-dimethyl-silanyloxy)-butyric acid cyclopentyl ester
  参考文献：
  名称：

  [EN] INHIBITORS OF IKK-ß SERINE-THREONINE PROTEIN KINASE
  [FR] INHIBITEURS DE SÉRINE-THRÉONINE PROTÉINE KINASE IKK-?

  摘要：

  环戊基(2S,4E)-2-氨基-5-{3-[4-羰胺基-5-(羰胺基氨基)-2-噻吩基]苯基}戊-4-烯酸酯；环戊基5-{3-[4-羰胺基-5-(羰胺基氨基)-2-噻吩基]苯基}-L-异戊酸酯；环戊基(2S,4E)-2-氨基-5-{3-[4-羰胺基-5-(羰胺基氨基)-2-噻吩基]-5-甲基苯基}戊-4-烯酸酯；环戊基(2S,4E)-2-氨基-5-{5-[4-羰胺基-5-(羰胺基氨基)-2-噻吩基]-2-甲基苯基}戊-4-烯酸酯；环戊基O-{3-[4-羰胺基-5-(羰胺基氨基)-2-噻吩基]苯基}-L-赖氨酸酯；环戊基O-{3-[4-羰胺基-5-(羰胺基氨基)-2-噻吩基]苯基}-L-赖氨酸酯；环戊基N-{3-[4-羰胺基-5-(羰胺基氨基)-2-噻吩基]苯基}-L-丙氨酸酯；和叔丁基N-{3-[4-羰胺基-5-(羰胺基氨基)-2-噻吩基]苯基}-L-丙氨酸酯通过细胞内羧酯酶水解为相应的羧酸，并可用于抑制IKKβ活性。

  公开号：

  WO2009130434A1

文献信息

• [EN] PYRROLO [2, 3-D] PYRIMIDINES AS INHIBITORS OF HSP90<br/>[FR] PYRROLO[2,3-D]PYRIMIDINES EN TANT QU'INHIBITEURS D'HSP90
  申请人：CHROMA THERAPEUTICS LTD

  公开号：WO2010043867A1

  公开（公告）日：2010-04-22

  The invention provides a compound compound which is (a) a pyrrolopyrimidine derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: wherein R1, R2, R3, R4 and W are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90, and also in the treatment of inflammation.

  这项发明提供了一种化合物，该化合物为（a）式（I）的吡咯吡嘧啶衍生物或其互变异构体，或（b）其药用可接受盐、N-氧化物、水合物或溶剂化合物：其中R1、R2、R3、R4和W的定义如本文所述。这些化合物在治疗由HSP90介导的疾病以及治疗炎症方面具有用处。
• INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE
  申请人：Moffat David Festus Charles

  公开号：US20110039920A1

  公开（公告）日：2011-02-17

  Cyclopentyl(2S,4E)-2-amino-5-3-[4-carbamoyl-5(carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norvalinate; Cyclopentyl(2S,4E)-2-amino-5-3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-5-methylphenyl}pent-4-enoate; Cyclopentyl(25,4E)-2-amino-5-5-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-2-methylphenyl}pent-4-enoate; Cyclopentyl O-3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl O-3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl N-3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate; and tert-Butyl N-3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate are hydrolysed to the corresponding carboxylic acids by intracellular carboxylesterases, and are useful for the inhibition of IKKβ activity.

  环戊基（2S,4E）-2-氨基-5-3-[4-羰基-5-(羰基氨基)-2-噻吩基]苯基}戊-4-烯酸环戊基5-3-[4-羰基-5-(羰基氨基)-2-噻吩基]苯基}-L-正丙酸酯环戊基（2S,4E）-2-氨基-5-3-[4-羰基-5-(羰基氨基)-2-噻吩基]-5-甲基苯基}戊-4-烯酸环戊基（25,4E）-2-氨基-5-5-[4-羰基-5-(羰基氨基)-2-噻吩基]-2-甲基苯基}戊-4-烯酸环戊基O-3-[4-羰基-5-(羰基氨基)-2-噻吩基]苯基}-L-异亮氨酸酯环戊基O-3-[4-羰基-5-(羰基氨基)-2-噻吩基]苯基}-L-异亮氨酸酯环戊基N-3-[4-羰基-5-(羰基氨基)-2-噻吩基]苯基}-L-丙氨酸酯和叔丁基N-3-[4-羰基-5-(羰基氨基)-2-噻吩基]苯基}-L-丙氨酸酯通过细胞内羧酯酶水解为相应的羧酸，并且对IKKβ活性的抑制是有用的。
• HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY
  申请人：Davidson Alan Hornsby

  公开号：US20090298924A1

  公开（公告）日：2009-12-03

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers: wherein Y 1 is a bond, —(C═O)—, —S(O 2 )—, —C(═O)O—, —OC(═O)—, —(C═O)NR 3 —, —NR 3 (C═O)—, —S(O 2 )NR 3 —, —NR 3 S(O 2 )—, or —NR 3 (C═O)NR 5 —, wherein R 3 and R 5 are independently hydrogen or optionally substituted (C 1 -C 6 )alkyl, L 1 is a divalent radical of formula -(Alk 1 ) m (O) n (Alk 2 ) p — wherein m, n, p, Alk 1 , Alk 2 and Q are as defined in the claims; z is 0 or 1; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker]- represents a divalent linker radical; R is a radical of formula (X) or (Y): wherein R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R 4 is hydrogen; or optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, aryl(C 1 -C 6 alkyl)-, heteroaryl, heteroaryl(C 1 -C 6 alkyl)-, —(C═O)R 3 , —(C═O)OR 3 , or —(C═O)NR 3 wherein R 3 is hydrogen or optionally substituted (C 1 -C 6 )alkyl, C 3 -C 7 cycloalkyl, aryl, aryl(C 1 -C 6 alkyl)-, heteroaryl, or heteroaryl(C 1 -C 6 alkyl)-; R 4 1 is hydrogen or optionally substituted C 1 -C 6 alkyl; and B is a monocyclic heterocyclic ring of 5 or 6 ring atoms wherein R 1 is linked to a ring carbon adjacent the ring nitrogen shown, and ring B is optionally fused to a second carbocyclic or heterocyclic ring of 5 or 6 ring atoms in which case the bond shown intersected by a wavy line may be from a ring atom in said second ring;

  式(I)的化合物是组蛋白去乙酰化酶活性的抑制剂，可用于治疗癌症等疾病：其中Y1是键，—(C═O)—、—S(O2)—、—C(═O)O—、—OC(═O)—、—(C═O)NR3—、—NR3(C═O)—、—S(O2)NR3—、—NR3S(O2)—或—NR3(C═O)NR5—，其中R3和R5分别是氢或可选取代的（C1-C6）烷基，L1是式-(Alk1)m(O)n(Alk2)p-的二价基团，其中m、n、p、Alk1、Alk2和Q如权利要求所定义；z为0或1；A代表可选取代的单环、双环或三环碳环或杂环系统；-[链接体]-代表二价的连接基团；R是式(X)或(Y)的基团：其中R1是羧酸基（—COOH），或可由一个或多个细胞内羧酸酯酶酶解为羧酸基的酯基；R4是氢；或可选取代的C1-C6烷基、C3-C7环烷基、芳基、芳基(C1-C6烷基)-、杂环芳基、杂环芳基(C1-C6烷基)-、—(C═O)R3、—(C═O)OR3或—(C═O)NR3，其中R3是氢或可选取代的（C1-C6）烷基、C3-C7环烷基、芳基、芳基(C1-C6烷基)-、杂环芳基或杂环芳基(C1-C6烷基)-；R41是氢或可选取代的C1-C6烷基；B是由5个或6个环原子组成的单环杂环，其中R1与所示的环氮相邻的环碳相连，并且环B可选择与第二个由5个或6个环原子组成的碳环或杂环融合，此时由波浪线相交的键可能来自于所述第二个环中的一个环原子。
• Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity
  申请人：Chroma Therapeutics Ltd.

  公开号：US07973181B2

  公开（公告）日：2011-07-05

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers: wherein Y1 is a bond, —(C═O)—, —S(O2)—, —C(═O)O—, —OC(═O)—, —(C═O)NR3—, —NR3(C═O)—, —S(O2)NR3—, —NR3S(O2)—, or —NR3(C═O)NR5—, wherein R3 and R5 are independently hydrogen or optionally substituted (C1-C6)alkyl, L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p wherein m, n, p, Alk1, Alk2 and Q are as defined in the claims; z is 0 or 1; A represents an optionally substituted mono-, bi— or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker]- represents a divalent linker radical; R is a radical of formula (X) or (Y): wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R4 is hydrogen; or optionally substituted C1-C6 alkyl, C3-C7cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, heteroaryl(C1-C6 alkyl)-, —(C═O)R3, —(C═O)OR3, or —(C═O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, or heteroaryl(C1-C6 alkyl)-; R41 is hydrogen or optionally substituted C1-C6 alkyl; and B is a monocyclic heterocyclic ring of 5 or 6 ring atoms wherein R1 is linked to a ring carbon adjacent the ring nitrogen shown, and ring B is optionally fused to a second carbocyclic or heterocyclic ring of 5 or 6 ring atoms in which case the bond shown intersected by a wavy line may be from a ring atom in said second ring.

  式(I)的化合物是组蛋白去乙酰化酶活性的抑制剂，可用于治疗癌症等疾病：其中Y1是键，-(C═O)-，-S(O2)-，-C(═O)O-，-OC(═O)-，-(C═O)NR3-，-NR3(C═O)-，-S(O2)NR3-，-NR3S(O2)-或-NR3(C═O)NR5-，其中R3和R5独立地为氢或可选取代的（C1-C6）烷基，L1是式-(Alk1)m(Q)n(Alk2)p的二价基团，其中m，n，p，Alk1，Alk2和Q如权利要求中所定义；z为0或1；A代表可选取代的单、双或三环碳环或杂环；-[连接基]-表示二价连接基团；R是式(X)或(Y)的基团：其中R1是羧酸基（-COOH），或可由一个或多个细胞内羧酸酯酶酶解为羧酸基的酯基；R4是氢；或可选取代的C1-C6烷基，C3-C7环烷基，芳基，芳基（C1-C6烷基）-，杂环芳基，杂环芳基（C1-C6烷基）-，-(C═O)R3，-(C═O)OR3或-(C═O)NR3，其中R3为氢或可选取代的（C1-C6）烷基，C3-C7环烷基，芳基，芳基（C1-C6烷基）-，杂环芳基或杂环芳基（C1-C6烷基）-；R41为氢或可选取代的C1-C6烷基；B为5或6个环原子的单环杂环，其中R1连接到所示的环氮旁的环碳，环B可选择与第二个5或6个环原子的碳环或杂环融合，在这种情况下，用波浪线相交的键可以来自所述第二个环中的环原子。
• PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  申请人：Moffat David Festus Charles

  公开号：US20100216802A1

  公开（公告）日：2010-08-26

  Compound of formula (I) are inhibitors of Polo-like kinases (PLKs), and are useful in treatment of cell proliferative diseases: wherein R 1 and R 2 are hydrogen, or an optionally substituted (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl or (C 3 -C 6 )cycloalkyl group; R 3 and R 3 ′ are independently selected from hydrogen, —CN, hydroxyl, halogen, optionally substituted (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl or (C 3 -C 6 )cycloalkyl, —NR 5 R 6 or C 1 -C 4 alkoxy, wherein R 5 and R 6 are independently hydrogen or optionally substituted (C 1 -C 6 )alkyl; ring A is an optionally substituted mono- or bi-cyclic carbocyclic or heterocyclic ring or a ring system having up to 12 ring atoms; T is a radical of formula R-L 1 -Y 1 — wherein R is an alpha amino acid or alpha amino acid ester motif, linked to ring A by linker R-L 1 -Y 1 — as defined in the claims.

  式(I)的化合物是Polo样激酶（PLKs）的抑制剂，可用于治疗细胞增殖性疾病：其中R1和R2是氢，或者是可选取代的（C1-C6）烷基，（C2-C6）烯基，（C2-C6）炔基或（C3-C6）环烷基；R3和R3'分别选自氢，—CN，羟基，卤素，可选取代的（C1-C6）烷基，（C2-C6）烯基，（C2-C6）炔基或（C3-C6）环烷基，—NR5R6或C1-C4烷氧基，其中R5和R6分别独立地是氢或可选取代的（C1-C6）烷基；环A是可选取代的单环或双环碳环或杂环，或具有多达12个环原子的环系；T是公式R-L1-Y1—的基团，其中R是α-氨基酸或α-氨基酸酯基序列，通过定义中的连接基R-L1-Y1—与环A相连。